Recent developments to share with you

CDMO One-Stop Services for the Full Drug R&D and Manufacturing Lifecycle – Kangchuanji's Successful Participation in the Nanjing QianTuHui Conference

2024-07-21


On July 18-19, the 88th Pharmaceutical QianTuHui Conference & National New Drug R&D and Investment M&A Summit was held at Nanjing Fengda International Hotel. Kangchuanji was invited to attend and set up a booth (Booth No. B02).

 

 

During the conference, Kangchuanji not only showcased our R&D strengths and product features but also provided a platform for meaningful exchanges. Our business team actively engaged with every visitor, listened to their needs, shared insights, and explored potential collaborations.

 

 

Although the conference has successfully concluded, our journey continues. Kangchuanji will keep a close eye on market demands, maintain close contact with industry clients, and provide better products and services to all our partners. We will turn the valuable information and inspiration gained at the conference into concrete actions, driving Kangchuanji's continued growth and contributing to the advancement of the industry.

 

 

We sincerely thank all the friends who visited our booth. Your support and trust are what drive us forward. Kangchuanji is always committed to providing you with better products and services, and we look forward to working with you!

Keywords:

Related information

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Good News | Kangchuanji Pharmaceutical’s Sildenafil Citrate Orally Disintegrating Tablets Have Been Approved for Market Launch

According to the drug approval document delivery information released by the NMPA, sildenafil citrate orally disintegrating tablets manufactured by Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. have been approved for marketing as a Class 4 generic drug under the new chemical drug registration classification, and are deemed to have passed the consistency evaluation.

2026-06-29

A Strong Start to the New Year – Kangchuanji Achieves Multiple Approvals

The new year begins with a wave of good news. Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd. has made an excellent start, backed by professional expertise. According to NMPA drug approval information, the following products have been approved for marketing or have passed consistency evaluation: Famotidine Injection (2ml:20mg), Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (2.5/1000mg and 5/1000mg), Isosorbide Dinitrate Tablets (5mg), Vitamin B6 Injection (100mg/ml), Cefdinir Granules (50mg/0.5g), and Ambroxol and Clenbuterol Oral Solution (1ml: ambroxol hydrochloride 1.5mg and clenbuterol hydrochloride 1μg). Among these, Isosorbide Dinitrate Tablets are the first in China to pass consistency evaluation. As a partner, Kangchuanji provided solid pharmaceutical R&D services, successfully supporting these drugs through the review and approval process.

2026-03-23